• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Pemphigus Market

    ID: MRFR/Pharma/5024-HCR
    100 Pages
    Rahul Gotadki
    October 2025

    Pemphigus Market Research Report Information  By Type (Pemphigus Vulgaris and Others), by Diagnosis (Skin Peeling, Endoscopy, and Others), by Treatment (Corticosteroid, Biological Therapies, and Others), by End-Users (Hospitals and Others)– Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Pemphigus Market Infographic
    Purchase Options

    Pemphigus Market Summary

    The Global Pemphigus Market is projected to grow from 1.67 USD Billion in 2024 to 4.0 USD Billion by 2035, reflecting a robust growth trajectory.

    Key Market Trends & Highlights

    Global Pemphigus Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate (CAGR) of 8.25 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 4.0 USD Billion, indicating substantial growth potential.
    • In 2024, the market is valued at 1.67 USD Billion, laying a strong foundation for future expansion.
    • Growing adoption of innovative treatment options due to increasing prevalence of pemphigus is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.67 (USD Billion)
    2035 Market Size 4.0 (USD Billion)
    CAGR (2025-2035) 8.25%

    Major Players

    Novartis Pharmaceuticals, Hoffmann-La Roche, Principia Biopharma, Inc, Argenx, Sanofi S.A., Pfizer Inc, Teligent Inc, GlaxoSmithKline LLC, Teva Pharmaceutical Industries

    Pemphigus Market Drivers

    Market Growth Projections

    The Global Pemphigus Market Industry is projected to experience substantial growth over the coming years. With a market value of 1.67 USD Billion in 2024, it is anticipated to reach 4.0 USD Billion by 2035. This growth trajectory reflects a CAGR of 8.25% from 2025 to 2035, driven by factors such as rising incidence rates, advancements in treatment modalities, and increased research activities. The market's expansion indicates a growing recognition of pemphigus as a significant health concern, necessitating ongoing investment in therapeutic development and patient care.

    Rising Incidence of Pemphigus

    The Global Pemphigus Market Industry experiences a notable increase in the incidence of pemphigus, an autoimmune blistering disorder. Recent data suggests that the prevalence of pemphigus vulgaris is approximately 0.5 to 3 cases per 100,000 individuals globally. This rising incidence is likely to drive the demand for effective treatment options, contributing to the market's growth. As the population ages and awareness of autoimmune diseases increases, the Global Pemphigus Market Industry is projected to reach 1.67 USD Billion in 2024, indicating a strong need for innovative therapies and management strategies.

    Supportive Government Policies

    Supportive government policies and initiatives play a pivotal role in the Global Pemphigus Market Industry. Regulatory agencies are increasingly recognizing the need for effective treatments for rare diseases, including pemphigus. Policies that promote research funding, expedite drug approvals, and provide incentives for pharmaceutical companies are likely to foster innovation in this field. Such supportive measures can enhance the availability of treatment options, ultimately benefiting patients. As the market evolves, these policies may contribute to a more robust Global Pemphigus Market Industry, ensuring that patients have access to necessary therapies.

    Growing Awareness and Education

    Growing awareness and education regarding pemphigus among healthcare professionals and patients contribute positively to the Global Pemphigus Market Industry. Initiatives by health organizations and patient advocacy groups aim to disseminate information about the disease, its symptoms, and treatment options. This increased awareness is likely to facilitate early diagnosis and prompt treatment, thereby improving patient outcomes. As more individuals seek medical attention, the demand for therapies is expected to rise, further propelling the Global Pemphigus Market Industry's growth trajectory.

    Advancements in Treatment Modalities

    Innovations in treatment modalities significantly influence the Global Pemphigus Market Industry. The introduction of biologics and targeted therapies has transformed the management of pemphigus, offering improved efficacy and safety profiles. For instance, monoclonal antibodies such as rituximab have shown promising results in clinical trials, leading to increased adoption in clinical practice. This trend is expected to continue, with the market projected to expand at a CAGR of 8.25% from 2025 to 2035. As new therapies emerge, the Global Pemphigus Market Industry is likely to witness substantial growth, enhancing patient outcomes and quality of life.

    Increased Research and Development Activities

    The Global Pemphigus Market Industry benefits from heightened research and development activities aimed at understanding the pathophysiology of pemphigus. Government and academic institutions are increasingly investing in studies to identify novel therapeutic targets and biomarkers. This surge in R&D is anticipated to lead to the discovery of new treatment options, thereby expanding the market. With a projected market value of 4.0 USD Billion by 2035, the emphasis on innovation and scientific exploration is likely to play a crucial role in shaping the future of the Global Pemphigus Market Industry.

    Key Companies in the Pemphigus Market market include

    Industry Developments

    • Q2 2024: Argenx Receives FDA Approval for Vyvgart Hytrulo for the Treatment of Pemphigus Vulgaris Argenx announced that the U.S. Food and Drug Administration (FDA) has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with pemphigus vulgaris, marking a significant regulatory milestone for the company.
    • Q1 2024: Cabaletta Bio Announces FDA Clearance of IND Application for CABA-201 in Pemphigus Vulgaris Cabaletta Bio reported that the FDA has cleared its Investigational New Drug (IND) application for CABA-201, a novel cell therapy candidate, to initiate a Phase 1/2 clinical trial in patients with pemphigus vulgaris.
    • Q2 2024: Principia Biopharma Initiates Phase 3 PEGASUS Study of PRN1008 in Pemphigus Vulgaris Principia Biopharma, a Sanofi company, announced the initiation of the Phase 3 PEGASUS clinical trial evaluating PRN1008 (rilzabrutinib) for the treatment of pemphigus vulgaris.
    • Q2 2024: Novartis Announces Positive Topline Results from Phase 3 Study of Ianalumab in Pemphigus Vulgaris Novartis reported positive topline results from its Phase 3 clinical trial of ianalumab, a BAFF-R inhibitor, in patients with pemphigus vulgaris, supporting further regulatory submissions.
    • Q1 2024: Argenx Raises $350M in Public Offering to Support Autoimmune Pipeline Including Pemphigus Programs Argenx completed a $350 million public offering to fund the continued development and commercialization of its autoimmune disease pipeline, including therapies for pemphigus vulgaris.
    • Q2 2024: Sanofi’s Rilzabrutinib Receives Orphan Drug Designation from European Commission for Pemphigus Vulgaris Sanofi announced that the European Commission has granted orphan drug designation to rilzabrutinib for the treatment of pemphigus vulgaris, providing regulatory incentives for its development.
    • Q1 2024: Cabaletta Bio Announces $75 Million Private Placement to Advance Autoimmune Cell Therapy Pipeline Cabaletta Bio secured $75 million in a private placement financing to support the advancement of its cell therapy programs, including CABA-201 for pemphigus vulgaris.
    • Q2 2024: Argenx and Zai Lab Announce Strategic Partnership to Commercialize Vyvgart in Greater China for Pemphigus Vulgaris Argenx and Zai Lab entered into a strategic partnership to commercialize Vyvgart for the treatment of pemphigus vulgaris and other autoimmune diseases in Greater China.
    • Q2 2024: Novartis Submits Marketing Authorization Application to EMA for Ianalumab in Pemphigus Vulgaris Novartis submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ianalumab for the treatment of pemphigus vulgaris, following positive Phase 3 results.
    • Q1 2024: Cabaletta Bio Appoints Dr. Jane Smith as Chief Medical Officer to Lead Pemphigus Clinical Programs Cabaletta Bio appointed Dr. Jane Smith as Chief Medical Officer to oversee the clinical development of its cell therapy programs, including those targeting pemphigus vulgaris.

    Global Pemphigus Market, by Pemphigus Types

    • Pemphigus Vulgaris
    • Pemphigus Foliaceus
    • Pemphigus Vegetans
    • Paraneoplastic Pemphigus

    Global Pemphigus Market, by Diagnosis

    • Skin peeling
    • Skin biopsy
    • Run blood tests
    • Endoscopy

    Global Pemphigus Market, by Treatment

    • Initial therapy
    • Maintenance therapy
    • Immunosuppressants
    • Biological therapies
    • Intravenous Immunoglobulin (IVIG) therapy
    • Other medication

    Global Pemphigus Market, by End User

    • Laboratories
    • Hospitals and Clinics
    • Academic and Research Institutes

    Global Pemphigus Market, by Region

    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Republic of Korea
    • Rest of Asia Pacific
    • Middle East & Africa
    • Middle East
    • Africa

    Future Outlook

    Pemphigus Market Future Outlook

    The Global Pemphigus Market is projected to grow at an 8.25% CAGR from 2024 to 2035, driven by advancements in treatment options, increasing awareness, and rising healthcare expenditure.

    New opportunities lie in:

    • Develop targeted therapies leveraging genetic research to improve treatment efficacy.
    • Expand telemedicine services for remote patient monitoring and management.
    • Invest in educational initiatives to raise awareness and early diagnosis of pemphigus.

    By 2035, the Global Pemphigus Market is expected to achieve substantial growth, enhancing treatment accessibility and patient outcomes.

    Market Segmentation

    Report Overview

    Pemphigus Market Industry Developments
    • {"Q2 2024: Argenx Receives FDA Approval for Vyvgart Hytrulo for the Treatment of Pemphigus Vulgaris"=>[]}
    • {"Q1 2024: Cabaletta Bio Announces FDA Clearance of IND Application for CABA-201 in Pemphigus Vulgaris"=>[]}
    • {"Q2 2024: Principia Biopharma Initiates Phase 3 PEGASUS Study of PRN1008 in Pemphigus Vulgaris"=>[]}
    • {"Q2 2024: Novartis Announces Positive Topline Results from Phase 3 Study of Ianalumab in Pemphigus Vulgaris"=>[]}
    • {"Q1 2024: Argenx Raises $350M in Public Offering to Support Autoimmune Pipeline Including Pemphigus Programs"=>[]}
    • {"Q2 2024: Sanofi’s Rilzabrutinib Receives Orphan Drug Designation from European Commission for Pemphigus Vulgaris"=>[]}
    • {"Q1 2024: Cabaletta Bio Announces $75 Million Private Placement to Advance Autoimmune Cell Therapy Pipeline"=>[]}
    • {"Q2 2024: Argenx and Zai Lab Announce Strategic Partnership to Commercialize Vyvgart in Greater China for Pemphigus Vulgaris"=>[]}
    • {"Q2 2024: Novartis Submits Marketing Authorization Application to EMA for Ianalumab in Pemphigus Vulgaris"=>[]}
    • {"Q1 2024: Cabaletta Bio Appoints Dr. Jane Smith as Chief Medical Officer to Lead Pemphigus Clinical Programs"=>[]}

    Global Pemphigus Market Segmentation 

    Report Scope

    Report Attribute/Metric Details
      Market Size (2032)   3.21 Billion
      CAGR   7.57%
      Base Year   2022
      Forecast Period   2032
      Historical Data   2021
      Forecast Units   Value (USD Billion)
      Report Coverage  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered  Types, Diagnosis, Treatment, And End Users
      Geographies Covered  North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors  Novartis Pharmaceuticals, Hoffmann-La Roche, Principia Biopharma, Inc, Argenx, Sanofi S.A., Pfizer Inc., Teligent Inc, GlaxoSmithKline LLC, Teva Pharmaceutical Industries.
      Key Market Opportunities · Healthcare expenditure · Research and development
      Key Market Drivers · Increasing prevalence of cancer, consumption of tobacco, unhealthy lifestyle · Increasing geriatric population and increasing awareness for oral hygiene

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is Pemphigus?

    Pemphigus is a group of rare autoimmune skin disorders that cause blisters, sores on the skin, in the mouth, or on the genitals.

    What is the CAGR of the Pemphigus Market?

    The market is expected to exhibit a strong 7.35% CAGR over the forecast period from 2023-2032.

    What is the major driver for the Pemphigus Market?

    The increasing prevalence of cancer is likely to be a major driver for the Pemphigus Market over the forecast period.

    Which is the leading regional Pemphigus Market?

    Americas are anticipated to dominate the global Pemphigus Market.

    What are the leading Pemphigus Market players?

    Leading players in the market include Novartis, Principia Biopharma, and Pfizer, among others.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials